+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

US Market for Diabetes Monitoring, Treatment and Drug Delivery 2014 (Forecasted to 2020) - MedSuite

  • ID: 3754275
  • Report
  • May 2014
  • Region: United States
  • 226 pages
  • iData Research

FEATURED COMPANIES

  • Abbott
  • Bayer
  • Covidien
  • Eli Lilly
  • LifeScan
  • Nipro Diagnostics
  • MORE
The diabetes monitoring, treatment and drug delivery market in the U.S. is expanding rapidly due to the increasing number of diabetics and the boom in modern insulin, insulin pens, and their accessories. This market will grow in conjunction with the number of diagnosed diabetics. Some segments will grow faster than others as the demand for modern and more efficient products is increasing faster than the rate of new diabetics. Conversely, reimbursement cuts and declining prices in some segments will affect the market negatively.

The diabetes monitoring, treatment and drug delivery market is segmented into eight categories. Among these, growing segments included the continuous glucose monitoring (CGM), insulin pump and supplies, modern insulin, insulin pens and pen needle markets. These segments have one aspect in common: they are newer ways of treating diabetes. CGM and pump technologies are improving at a fast pace toward full integration and automatic insulin suspension. Modern insulin is rapidly replacing human insulin due to its superior qualities. Insulin pens are replacing insulin syringes because they are discreet, more accurate and require less time. These segments will drive the overall market up through 2020.

The blood glucose test strip market suffered a blow in 2013 after Medicare decided to slash reimbursement rates for diabetes supplies significantly.

The modern insulin market is composed of three segments: long-acting, rapid-acting and premixed modern insulin.

Some of the diabetic population will always use syringes; nevertheless, this segment will become trivial over the forecast period. Insulin syringes once enjoyed complete dominance in the U.S. market.

Pen needles fit almost all insulin pens in the U.S. market; they are universal in that sense. This feature allows smaller companies, such as Allison Medical Inc., CanAm Care, and Owen Mumford, to sell their products with major pen brands.

The insulin pump market is a growing segment as some diabetics switch to pumps to avoid multiple daily injections.
Note: Product cover images may vary from those shown
Sanofi
Novo Nordisk
Eli Lilly
LifeScan
Medtronic
Roche
Abbott
Becton Dickinson
Bayer
Nipro Diagnostics
Insulet Corporation
Animas
DexCom
Nova Biomedical
Covidien
Owen Mumford
Valeritas
Note: Product cover images may vary from those shown
Adroll
adroll